Your DNA May Predict Weight Loss on GLP-1 Drugs

Imagine knowing before you start a weight loss medication whether it will work for you. That future just got closer.

Researchers at 23andMe found that specific changes in two genes can predict how well someone will respond to GLP-1 drugs, the blockbuster medications now prescribed for obesity. The same genetic markers also indicate who might experience nausea or vomiting, the most common side effects.

"I think we have proof of concept here that genetics is playing a role in terms of GLP-1 efficacy and side effects," said Adam Auton, vice president at the 23andMe Research Institute. His team published their findings in Nature this week.

The discovery matters because these medications don't work equally well for everyone. Some patients lose substantial weight while others see minimal results. Until now, doctors had no way to predict who would benefit most.

The research team analyzed genetic data from thousands of patients taking GLP-1 medications. They identified two specific genes where variations correlated strongly with treatment outcomes. People with certain versions of these genes tended to lose more weight. Others were more likely to experience uncomfortable side effects.

Outside researchers called the findings impressive and intriguing. Some questioned whether the genetic information would immediately change how doctors prescribe these medications. But the research opens doors to more personalized treatment approaches.

The Ripple Effect

The implications extend beyond individual patients. As obesity affects over 40% of American adults, any tool that helps match the right treatment to the right person could transform care for millions. Insurance companies might eventually use this information to guide coverage decisions, making expensive medications available to those most likely to benefit.

23andMe is already moving forward. Users of their Total Health platform can now access information about these genetic markers and what they might mean for GLP-1 treatment. This puts personalized medicine directly in consumers' hands.

The research represents a broader shift in healthcare toward precision medicine. Rather than one-size-fits-all treatments, doctors increasingly use genetic information to tailor therapies to individual patients. This approach has already revolutionized cancer care and now shows promise for obesity treatment.

For the millions of Americans considering these medications, genetic testing could soon become a standard first step, helping them make informed decisions with their doctors about whether GLP-1 drugs are their best path forward.